Acta Scientific Neurology (ASNE) (ISSN: 2582-1121)

Review Article Volume 4 Issue 2

Cannabinoid Therapy for Glioblastoma Treatment: A Review

Marcos Escosa Bagé*

Department of Neurosurgery, CHIP Hospital Complex, Spain

*Corresponding Author: Marcos Escosa Bagé, Department of Neurosurgery, CHIP Hospital Complex, Spain.

Received: October 26, 2020; Published: January 22, 2021



In recent years, studies have brought to light preclinical evidence of the ability of cannabinoids to reduce tumor growth in animal models, and clinical trials have been designed to study this activity in patients with glioblastoma. The data in animal models show promising results. So far it has been seen that the administration of THC is safe, and can be carried out without psychoactive effects. These molecules act through receptors coupled to the G protein, which are part of the endocannabinoid system and which have been called CB1 and CB2. THC can attenuate tumor progression in some patients, and appears to have a positive effect on survival, similar to that generated by other chemotherapeutic agents. More trials are needed to validate this antitumor action, both in combination with other therapies, and independently. At this time there is not enough scientific evidence to be able to conclusively affirm that cannabinoid treatment can contribute improve current therapies given to patients with brain tumors or other types of tumors.

Keywords: Glioblastoma; Endocannabinoid System; Antitumor Therapy



  1. Montero-Oleas N., et al. “Therapeutic use of cannabis and cannabinoids: an evidence mapping and appraisal of systematic reviews”. BMC Complementary Medicine and Therapies1 (2020): 12.
  2. Laezza C., et al. “The endocannabinoid system: A target for cancer treatment”. International Journal of Molecular Sciences3 (2020): 747.
  3. Turgeman I and Bar-Sela G. “Cannabis for cancer–illusion or the tip of an iceberg: A review of the evidence for the use of Cannabis and synthetic cannabinoids in oncology”. Expert Opinion on Investigational Drugs3 (2019): 285-296.
  4. Luís Â., et al. “The effects of cannabinoids on glioblastoma growth: A systematic review with meta-analysis of animal model studies”. European Journal of Pharmacology 4 (2020): 173055.
  5. Silver RJ. “The endocannabinoid system of animals”. Animals9 (2018): 686.
  6. Śledziński P., et al. “The current state and future perspectives of cannabinoids in cancer biology”. Cancer Medicine3 (2018): 765-775.
  7. Hinz B and Ramer R. “Anti‐tumour actions of cannabinoids”. British Journal of Pharmacology10 (2019): 1384-1394.
  8. Torres-Román AL., et al. “Oleamide Induces Cell Death in Glioblastoma RG2 Cells by a Cannabinoid Receptor–Independent Mechanism”. Neurotoxicity Research 15 (2020): 1-6.
  9. Guzman M., et al. “A pilot clinical study of Δ 9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme”. British Journal of Cancer2 (2006): 197-203.
  10. Colella B., et al. “EMT regulation by autophagy: a new perspective in glioblastoma biology”. Cancers 3 (2019): 312.
  11. Sordillo LA., et al. “Sphingosine kinase inhibitors as maintenance therapy of glioblastoma after ceramide-induced response”. Anticancer Research5 (2016): 2085-2095.
  12. Ellert-Miklaszewska A., et al. “Cannabinoid signaling in glioma cells”. InGlioma Signaling (2013): 209-220.
  13. Lorente M., et al. “Stimulation of the midkine/ALK axis renders glioma cells resistant to cannabinoid antitumoral action”. Cell Death and Differentiation6 (2011): 959-973.
  14. Velasco G., et al. “Anticancer mechanisms of cannabinoids”. Current Oncology 23 (2016): S23.
  15. Russo EB. “Taming THC: potential cannabis synergy and phytocannabinoid‐terpenoid entourage effects”. British Journal of Pharmacology7 (2011): 1344-1364.
  16. Pertwee RG. “The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9‐tetrahydrocannabinol, cannabidiol and Δ9‐tetrahydrocannabivarin”. British Journal of Pharmacology2 (2008): 199-215.
  17. Devinsky O., et al. “Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders”. Epilepsia6 (2014): 791-802.
  18. Iuvone T., et al. “Cannabidiol: a promising drug for neurodegenerative disorders?”. CNS Neuroscience and Therapeutics1 (2009): 65-75.
  19. Rodrigues RS., et al. “Cannabinoid Actions on Neural Stem Cells: Implications for Pathophysiology”. Molecules7 (2019): 1350.
  20. Billakota S., et al. “Cannabinoid therapy in epilepsy”. Current Opinion in Neurology2 (2019): 220-226.
  21. Colizzi M and Bhattacharyya S. “Does cannabis composition matter? Differential effects of delta-9-tetrahydrocannabinol and cannabidiol on human cognition”. Current Addiction Reports2 (2017): 62-74.
  22. Hinz B and Ramer R. “Anti‐tumour actions of cannabinoids”. British Journal of Pharmacology10 (2019): 1384-1394.
  23. Gustafsson SB., et al. “Cannabinoid receptor-independent cytotoxic effects of cannabinoids in human colorectal carcinoma cells: synergism with 5-fluorouracil”. Cancer Chemotherapy and Pharmacology4 (2009): 691-701.
  24. de la Ossa DH., et al. “Local delivery of cannabinoid-loaded microparticles inhibits tumor growth in a murine xenograft model of glioblastoma multiforme”. PLoS One1 (2013): e54795.
  25. Yan Y., et al. “Targeting autophagy to sensitive glioma to temozolomide treatment”. Journal of Experimental and Clinical Cancer Research 1 (2016): 23.
  26. Esposito G., et al. “The Endocannabinoid System Protects Rat Glioma Cells Against HIV-1 Tat Protein-induced Cytotoxicity MECHANISM AND REGULATION”. Journal of Biological Chemistry52 (2002): 50348-50354.
  27. Guzman M., et al. “A pilot clinical study of Δ 9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme”. British Journal of Cancer2 (2006): 197-203.
  28. GW Pharmaceuticals plc. GW Pharmaceuticals Achieves Positive Results in Phase 2 Proof of Concept Study in Glioma (2017).
  29. López-Valero I., et al. “Targeting Glioma Initiating Cells with A combined therapy of cannabinoids and temozolomide”. Biochemical Pharmacology 157 (2018): 266-274.
  30. López-Valero I., et al. “Optimization of a preclinical therapy of cannabinoids in combination with temozolomide against glioma”. Biochemical Pharmacology 157 (2018): 275-284.


Citation: Marcos Escosa Bagé. “Cannabinoid Therapy for Glioblastoma Treatment: A Review”. Acta Scientific Neurology 4.2 (2021): 10-16.


Acceptance rate32%
Acceptance to publication20-30 days

Indexed In

News and Events

  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is May 20, 2024.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of "Best Article of the Issue"
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.

Contact US